Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial (Q42647640)

4 November 2017

title

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial (English)

1 reference

4 November 2017

main subject

phase II clinical trial

0 references

0 references

0 references

2

Hans-Peter Hartung

1 reference

4 November 2017

1

Ludwig Kappos

1 reference

4 November 2017

Mark S Freedman

3

1 reference

4 November 2017

Alexey Boyko

4

1 reference

4 November 2017

Ernst Wilhelm Radü

5

1 reference

4 November 2017

Daniel D Mikol

6

1 reference

4 November 2017

Marc Lamarine

7

1 reference

4 November 2017

Yann Hyvert

8

1 reference

4 November 2017

Ulrich Freudensprung

9

1 reference

4 November 2017

Thomas Plitz

10

1 reference

4 November 2017

Johan van Beek

11

1 reference

4 November 2017

ATAMS Study Group

12

1 reference

4 November 2017

publication date

6 March 2014

1 reference

4 November 2017

1 reference

4 November 2017

volume

13

1 reference

4 November 2017

issue

4

1 reference

4 November 2017

page(s)

353-363

1 reference

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

BLyS and APRIL in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

The expression of BAFF-binding receptors is not altered in multiple sclerosis or myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

B cells and antibodies in multiple sclerosis pathogenesis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Estimation of reliability in a three-factor model

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Specific peripheral B cell tolerance defects in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Airway epithelial cells produce B cell-activating factor of TNF family by an IFN-beta-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970028-6

7 January 2021

10.1016/S1474-4422(14)70028-6

Identifiers

DOI

1 reference

4 November 2017

1 reference